Merck & Co.
2000 Galloping Hill Road
About Merck & Co.
About our Company
We aspire to be the premier research-intensive biopharmaceutical company in the world. Innovation and scientific excellence are at the core of what we do in pursuit of our mission to save and improve lives. Together, we invent for a more hopeful future.
Who we are
Our company, Merck (known as MSD outside of the U.S. and Canada), is a global health care leader with a diversified portfolio of prescription medicines, vaccines, and animal health products. For more than 125 years we have been inventing for life. Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases like HIV and Ebola, and emerging animal diseases.
We hire the most brilliant minds because inventing for life depends on our work. Our dedicated employees come from an array of backgrounds and do many different things --from research and development and business technology to marketing and pharmaceutical sales. Yet each of us knows our work matters.
At Merck, you'll find rewarding opportunities, diverse experiences, and an unwavering commitment to ethics and integrity. You'll collaborate with talented colleagues who share your sense of purpose. Our company will empower you to innovate, explore, and develop your full potential in our possibility-rich environment. Join our team and help us invent, impact, and inspire every day.
3483 articles with Merck & Co.
Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials of molnupiravir, an investigational oral antiviral therapeutic.
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation.
The expanded approval was made based on positive data from a second interim analysis of the Phase II KEYNOTE-629 trial.
NGM Biopharmaceuticals and Merck announced they had amended their existing collaboration agreement. It will continue through March 2024, but have a narrower scope.
NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular and Metabolic (CVM) Diseases
NGM Biopharmaceuticals, Inc. announced that the company has entered into an amended and restated agreement with Merck, known as MSD outside the United States and Canada, to extend their ongoing collaboration through March 2024 but with a narrower scope.
Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)
Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA ® (pembrolizumab)
Alpine Immune Sciences has entered into a collaboration agreement with Merck to evaluate the efficacy and safety of Alpine’s checkpoint in combination with Merk’s anti-PD-1 therapy in cancer.
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
Merck announced that the EC has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or human epidermal growth factor receptor 2 -negative gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1.
If approved, lenacapavir would be offered to HIV patients who have been heavily treated for the disease and have multi-drug-resistant HIV.
Here’s a look at some of the top COVID-19-related stories for today.
LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that LYNPARZA has been granted conditional approval in China as monotherapy for the treatment of adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment that included a new hormonal agent.
Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
Merck, known as MSD outside the United States and Canada, announced that the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy with or without bevacizumab, met its primary endpoints of overall survival and progression-free survival for the first-line treatment of patients with persistent, recurrent or metastatic cervical cancer.
Merck announced that Dr. Dean Li, executive vice president and president, Merck Research Laboratories, is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series with Senior Management to discuss Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation on June 22, 2021, at 9:00 a.m. EDT.
XTX101 is a tumor-selective anti-CTLA-4 monoclonal antibody designed to improve upon the safety of current therapies in the same class.
Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All
Merck announced today the creation of the Kenneth C. Frazier Award for Maternal Health Equity, a grant award that will be bestowed annually to one organization in recognition of its commitment to and progress toward more equitable, high-quality maternal health care.
6/14/2021A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more.
Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration
The $7 billion transaction by Datavant with Ciox Health will be the nation's largest "neutral and secure health data ecosystem."
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Results From New Analysis Evaluating Health-Related Quality of Life (HRQoL) Based on Patient-Reported Outcomes Using Three HRQoL Scales
An ugly symbol of racism appears to have reared its head at a Merck facility in North Carolina. The pharma giant is investigating reports of a noose found hanging at a construction project on the 262-acre facility.